Sign In
Buy CMPS
$12.69
-0.640 (-4.80%)
At Close: Jun 03, 2026
Why Compass Pathways Stock Slumped This Week
08:17am, Friday, 12'th Nov 2021
Positive trial results weren't enough to keep the company's shares from sinking this week.
Behind the Wall: Psychedelics Have “Absolutely Transformational” Potential
10:42am, Thursday, 11'th Nov 2021
Is now the time to invest in psychedelic stocks? Dustin Robinson, founder of venture capital firm Iter Investments, says yes and explains why.
Is Compass Pathways Stock a Once-in-a-Lifetime Bargain?
10:00am, Thursday, 11'th Nov 2021
Investors might want to give this psychedelic stock another look.
Why Compass Pathways Shares Are Slumping More Than 22% Tuesday
03:48pm, Tuesday, 09'th Nov 2021
The stock dropped more than $13 on Tuesday.
Compass Pathways' Psilocybin Therapy Shows Mixed Results From Depression Trial
08:52am, Tuesday, 09'th Nov 2021
Compass Pathways plc (NASDAQ: CMPS) has announced results from Phase 2b trial of COMP360 psilocybin therapy for treatment-resistant depression. The study has achieved its primary end
Down 25% in 2021, Is Compass Pathways Undervalued?
06:55am, Friday, 22'nd Oct 2021
It depends on how optimistic you are about its lead program.
COMPASS Pathways is granted new US patent for crystalline psilocybin
07:00am, Tuesday, 19'th Oct 2021
London, UK – 19 October 2021 COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health,
Why Compass Pathways Stock Dropped 12% in September
06:29pm, Tuesday, 05'th Oct 2021
Progress continues on the company's work to develop a mental health treatment using a psychoactive drug therapy.
COMPASS Pathways to participate in upcoming Maxim and Cantor investor conferences
08:00am, Tuesday, 21'st Sep 2021
London, UK, Sept. 21, 2021 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health,
Is the Options Market Predicting a Spike in COMPASS Pathways (CMPS) Stock?
10:43am, Monday, 20'th Sep 2021
Investors need to pay close attention to COMPASS Pathways (CMPS) stock based on the movements in the options market lately.
Compass: Psychedelics Unicorn Expands Portfolio Beyond Psilocybin Into Psychedelics 2.0
03:39pm, Wednesday, 15'th Sep 2021
Psychedelics biotech company Compass Pathways (NASDAQ:CMPS) has purchased an intellectual property portfolio that includes patent applications for a variety of psychedelic and empathogenic substances.
COMPASS Pathways acquires IP portfolio of novel psychedelic compounds and prodrugs
07:00am, Tuesday, 14'th Sep 2021
COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced that it has acquired
Hamilton Morris joins COMPASS Pathways to research new psychedelic compounds
07:00am, Friday, 10'th Sep 2021
COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, has engaged Hamilton Morris, t
Time to Buy the Magic Stocks? Magic Mushrooms, That Is.
12:39pm, Wednesday, 08'th Sep 2021
The first state to legalize cannabis for medical use was California, in 1996. In 2001, medical marijuana was approved in Canada.
COMPASS Pathways to participate in Citi, Morgan Stanley and HC Wainwright investor conferences in September
10:00am, Tuesday, 07'th Sep 2021
London, UK – 7 September 2021, Sept. 07, 2021 (GLOBE NEWSWIRE) -- London, UK – 7 September 2021 COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to a
